Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) has earned an average rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $39.67.

Several research analysts have recently weighed in on the stock. Mizuho dropped their target price on shares of Cerevel Therapeutics from $32.00 to $28.00 and set a "neutral" rating on the stock in a research report on Thursday, November 10th. JPMorgan Chase & Co. dropped their target price on shares of Cerevel Therapeutics from $49.00 to $40.00 and set an "overweight" rating on the stock in a research report on Tuesday, December 6th. The Goldman Sachs Group raised their price target on shares of Cerevel Therapeutics from $24.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, September 21st. Wells Fargo & Company started coverage on shares of Cerevel Therapeutics in a report on Monday, September 26th. They set an "overweight" rating and a $38.00 price target for the company. Finally, HC Wainwright decreased their price target on shares of Cerevel Therapeutics from $50.00 to $48.00 and set a "buy" rating for the company in a report on Wednesday, November 9th.

Insider Buying and Selling

In related news, CEO N Anthony Coles sold 50,000 shares of the business's stock in a transaction on Friday, December 9th. The shares were sold at an average price of $26.67, for a total transaction of $1,333,500.00. Following the transaction, the chief executive officer now owns 2,704 shares of the company's stock, valued at $72,115.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cerevel Therapeutics

Cerevel Therapeutics Trading Down 1.3 %

Shares of NASDAQ:CERE opened at $32.79 on Friday. The company has a market cap of $5.13 billion, a PE ratio of -15.39 and a beta of 1.47. The company's 50-day moving average price is $29.13 and its 200 day moving average price is $29.12. Cerevel Therapeutics has a fifty-two week low of $19.86 and a fifty-two week high of $41.46. The company has a quick ratio of 16.64, a current ratio of 16.64 and a debt-to-equity ratio of 0.56.

Cerevel Therapeutics (NASDAQ:CERE – Get Rating) last released its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.04). Sell-side analysts anticipate that Cerevel Therapeutics will post -2.36 earnings per share for the current year.

Cerevel Therapeutics Company Profile

(Get Rating)

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety.

Recommended Stories

• Get a free copy of the StockNews.com research report on Cerevel Therapeutics (CERE)
• MarketBeat: Week in Review 01/09-01/13
• JPMorgan Chase Falls As Banks Brace For Recession
• Why is the Bed Bath & Beyond Stock Price up 261%?
• Roku Stock Price is Trending, Here's Why
• Carvana Stock Rally, Here's What You Need to Know

Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.